New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.43 1.09 +1.87%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 13.2% in Q3 FY26, against a low of 11.0% in Q4 FY25. ROE, at 44.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE40.4%38.8%46.6%44.0%
ROIC11.0%11.1%13.7%13.2%

Debt

Net debt is 9.58× a year’s EBITDA. Debt is 1.83× equity, against 2.44× in Q4 FY25.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity2.4×2.2×1.9×1.8×
Net debt / EBITDA14.1×8.9×6.8×9.6×

Cash cycle, in days

Customers pay in 78 days, inventory is held 64 days and suppliers are paid in 110. Cash is tied up for 32 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle63334332
Days to pay suppliers94108103110
Days to be paid86717878

Per share, from Q4 FY25

Since Q4 FY25, per share: free cash flow has fallen 28.0%; revenue has grown 3.36%; book value has grown 25.9%.

Free cash flowRevenueBook value
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Free cash flow1.0×0.9×0.9×0.7×
Revenue1.0×1.0×1.0×1.0×
Book value1.0×1.1×1.2×1.3×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

15.59 17.04 12.69 13.81
P/S ratio
2.28 2.55 2.39 2.55
P/FCF ratio
8.54 10.38 10.29 13.73
P/Operating CF
55.58 111.96 34.68 30.49
P/B ratio
5.93 6.15 5.27 5.45
EV/Sales
2.99 3.25 3.04 3.15
EV/EBITDA
10.81 11.95 9.92 11.17
EV/FCF
11.22 13.23 13.09 16.99
Current Ratio
1.26 1.42 1.53 1.59
Net Debt/EBITDA
14.06 8.86 6.85 9.58
Debt/Equity
2.44 2.21 1.93 1.83
Earnings Yield
6.41% 5.87% 7.88% 7.24%
Free Cash Flow Yield
11.71% 9.63% 9.72% 7.28%
Free Cash Flow per Share
0.79 0.37 1.51 1.88
Book value per Share
9.10 9.86 10.93 11.46
Free Cash Flow
1,604.00 757.00 3,088.00 3,837.00
EV/EBIT
15.45 16.42 12.57 13.92
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026